ABILITYPHARMA

Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company

PIPELINE

ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France

SCIENCE

AbilityPharma investigates cancer drugs inducing autophagy through the overexpression of TRIB3 and the inhibiton of the PI3K/Akt/mTOR pathway

ONGOING PHASE 2 CLINICAL TRIAL AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED/METASTATIC ENDOMETRIAL CANCER OR LUNG CANCER - NOW RECRUITING PATIENTS AT VALL D'HEBRON INSTITUTE OF ONCOLOGY VHIO (BARCELONA), INSTITUT CATALÀ D'ONCOLOGIA (L’HOSPITALET, BADALONA AND GIRONA), INCLIVA (VALENCIA) AND HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO (SEVILLA) - RECRUITING PATIENTS IN PARIS, MARSEILLE AND LYON IN FALL 2017

AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and with one product, ABTL0812, an oral autophagy targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC, is positioning itself as one of the fast growers in the Catalan and Spanish biotech sector.

Media Center

18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
11.10.2016

Publications

Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling + info
15.05.2016

Publications

The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase + info
November.2017

Events

2017 BioEurope. (Berlin - Germany) + info
June.2017

Events

2017 BIO International Convention. San Diego, CA (USA) + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits